Uterine leiomyomas are benign, yet extremely common tumours affecting up to 70% of women by age 50 years ([@bib4]). Although the majority are asymptomatic, approximately 25% of affected women display symptoms including abnormal uterine bleeding and abdominal pain that require medical attention ([@bib46]). As conservative therapies leave room for improvement, patients frequently end up undergoing hysterectomy. Consequently, the economic and health impact of leiomyomas is enormous: the estimated annual health-care-related costs of uterine leiomyomas range from 6 to 34 billion USD in the United States ([@bib10]).

Leiomyomas are oestrogen- and progesterone-dependent tumours that consist of slowly proliferating smooth muscle cells surrounded by abundant extracellular matrix ([@bib29]). An affected uterus may contain multiple leiomyomas that vary greatly in size and may exceed 20 cm in diameter ([@bib12]). Molecular analyses have revealed that leiomyomas harbour mutually exclusive driver mutations ([@bib31]; [@bib35]; [@bib27]). The most frequent of these are *mediator complex subunit 12* (*MED12*) mutations ([@bib39]) and *high mobility group AT-hook 2* (*HMGA2*) translocations ([@bib45]), which affect approximately 80% and 10% of uterine leiomyomas, respectively ([@bib35]). Heterozygous germline mutations in the tricarboxylic acid (TCA) cycle enzyme *fumarate hydratase* (*FH*) cause hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome, characterised by predisposition to type 2 papillary renal cell carcinoma, as well as uterine and cutaneous leiomyomas ([@bib49]). These syndromic tumours display a somatic second-hit mutation in *FH*, resulting in the complete loss of FH activity in neoplastic cells. Biallelic inactivation of *FH* accounts for only 1% of sporadic leiomyomas ([@bib28]). Different downstream mechanisms are likely to lead to the development of leiomyomas, as these three genetic-driver changes result in clearly distinct gene expression profiles ([@bib34]).

Reprogramming of metabolic pathways is a hallmark feature of neoplastic growth and therapeutic targeting of metabolic alterations is a promising strategy to control the process ([@bib47]; [@bib43]). To our knowledge, no prior studies exploring the whole metabolome of leiomyomas exist. Here we used untargeted metabolomic analysis to determine the pathophysiology of leiomyomas and the metabolic processes that enable tumour growth and development. This study explored the global metabolomic profile of 25 leiomyomas, harbouring different genetic-driver alterations including defects in *FH*, *MED12*, or *HMGA2*, and 17 respective normal myometrium samples. Furthermore, we integrated metabolomic and gene expression data to gain a deeper understanding of the molecular networks that are dysregulated in leiomyomas. We identified several metabolic alterations common for all leiomyomas and distinctive characteristics for leiomyomas of the *FH* and *MED12* subtypes.

Materials and methods
=====================

Subjects
--------

The study material was derived from sample collections described in our previous work ([@bib39]; [@bib24]; [@bib23]; [@bib34]). Briefly, uterine leiomyoma and corresponding myometrial tissue samples were collected from patients undergoing hysterectomy in Finland between 2002 and 2015 and stored fresh frozen at −80 °C. Samples from five patients (series M) were obtained anonymously with the approval of the director of the health-care unit. The other patients (series B, My, and N) signed an informed consent, and clinical data were available from their patient records. The appropriate Ethics Review Board of Helsinki University Hospital, Finland approved this study.

Sample selection
----------------

The study samples were selected based on our previous work: seven leiomyomas were *FH* deficient (three from HLRCC patients), seven harboured a mutation in *MED12*, two displayed *HMGA2* overexpression, and nine were mutation negative for all three, henceforth termed triple wild-type leiomyomas. These 25 leiomyomas were obtained from 17 patients from whom normal myometrium samples were also included in the study.

All samples were screened for *MED12* hotspot mutations using Sanger sequencing ([@bib27]). Deletions and rearrangements affecting *FH* or *HMGA2* loci were detected using whole-genome sequencing and/or SNP arrays ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}) ([@bib34]). All tumours with 1q deletion and corresponding normal samples were screened for *FH* mutations using Sanger sequencing ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}) ([@bib27]). The relative quantification of *HMGA2* expression was determined in all samples with rearrangements or deletions affecting *HMGA2* using gene expression data ([@bib34]) or *HMGA2* qPCR, performed on a 7500 Fast Real-Time PCR System with Assay No. Hs04397751_m1 (Applied Biosystems, Darmstadt, Germany), using 18S rRNA as endogenous control ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}).

Gene expression profiling
-------------------------

A total of 94 leiomyomas, including 10 with biallelic loss of *FH*, 34 with a *MED12* mutation, 27 with an *HMGA2* rearrangement and 23 triple wild-type leiomyomas, and 60 corresponding myometrium samples were assayed with Affymetrix GeneChip Human Exon 1.0 ST arrays. The gene expression profiling is described in detail in [@bib34]).

Metabolomic profiling
---------------------

Metabolomic profiling was performed by Metabolon Inc. (Durham, NC, USA) as described previously ([@bib36]). Briefly, samples were analysed using four independent platforms: two reverse phase/ultra-performance liquid chromatography--tandem mass spectroscopy (RP/UPLC-MS/MS) methods with positive ion mode electrospray ionisation (ESI) chromatographically optimised separately for hydrophilic and hydrophobic compounds, one for analysis by RP/UPLC-MS/MS with negative ion mode ESI, and one for analysis by hydrophilic interaction chromatography/UPLC-MS/MS with negative ion mode ESI. All methods used an ACQUITY UPLC (Waters, Milford, MA, USA) and a Q-Exactive high-resolution/accurate mass spectrometer (Thermo Scientific Inc., Waltham, MA, USA) interfaced with a heated electrospray ionisation (HESI-II) source and Orbitrap mass analyser operated at 35 000 mass resolution. A pooled matrix sample of each experimental sample served as a technical replicate; extracted water samples served as process blanks; and a cocktail of quality-control standards spiked into every analysed sample allowed instrument performance monitoring and aided chromatographic alignment. Compounds were identified by comparison to library entries of purified standards or recurrent unknown entities. Peaks were quantified using area under the curve.

To replicate the clustering results, a targeted analysis of 102 metabolites on 10 normal myometrium samples of uterine leiomyoma patients was carried out at the Metabolomics Unit, Technology Centre, Institute for Molecular Medicine Finland FIMM, University of Helsinki as previously described ([@bib40]).

Statistical analysis
--------------------

Statistical analyses were performed with Partek Genomics Suite version 6.6 (Partek Inc., St Louis, MO, USA). Raw data of each metabolite were rescaled to set the median to 1 and log~2~ transformed. Missing values were imputed with the minimum observed value for each compound. Principal component analysis (PCA) was performed for all samples. Unsupervised hierarchical clustering analysis (cosine dissimilarity) was performed using all metabolites. The PCA and the unsupervised hierarchical clustering analysis revealed five outlier samples (M4 m2, M4 m3, M4 N, M11 m2, and M11 N), all of which were derived from two individual patients (M4 and M11). Both normal samples were also outliers in the replication data set ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). These outlier samples were interpreted as biological outliers and therefore included in the subsequent analyses.

To evaluate whether tumour size (largest diameter) correlated with any of the metabolite levels, we calculated Pearson's correlation coefficients. A two-way ANOVA, with tissue type and patient-of-origin as factors, was constructed to identify metabolites that were dysregulated between leiomyomas and the corresponding myometrium samples. A one-way ANOVA, with tissue type as a factor, was constructed to identify metabolites that were dysregulated in each leiomyoma subtype (*FH*, *MED12*, *HMGA2*, and triple wild type) as compared with all myometrium samples. The 20 most significant metabolites from each comparison, yielding 63 unique metabolites, were used for supervised hierarchical clustering analysis (cosine dissimilarity) of all tumour and normal samples. To identify the most uniquely dysregulated metabolites for leiomyomas of *MED12* and *FH* subtypes, two three-way ANOVA tests, with mutation status (mutation positive or negative), tissue type, and patient-of-origin as factors, were constructed that compared each subtype against the rest of the leiomyoma and myometrium samples. To identify dysregulated main categories of metabolites between each leiomyoma subtype (*FH*, *MED12*, *HMGA2*, and triple wild type) and all myometrium samples, we used the Partek GO-ANOVA function (metabolite set ANOVA) with metabolites grouped into nine main categories. To explore whether any of the 86 metabolic pathways were significantly dysregulated, a pathway enrichment analysis was performed with the significant metabolites (*q*-value \<0.1) for each leiomyoma subtype. False discovery rate control was used to correct for multiple testing ([@bib5]).

Ingenuity pathway analysis
--------------------------

Ingenuity pathway analysis (IPA) was carried out with each set of significantly dysregulated metabolites (*q*-value \<0.1) and each set of significantly differentially expressed genes (*q*-value \<0.1, \|fold change (FC)\|\>1.5) using IPA software version 33559992 (Qiagen, Redwood City, CA, USA). We used IPA's comparison tool to identify pathways that were significantly dysregulated in both the metabolomic and gene expression data (*P*-value \<0.05 in both) for leiomyomas of the *FH*, *MED12*, and *HMGA2* subtypes. We excluded the triple wild-type leiomyomas from the analyses due to their heterogeneity in the clustering analyses. Ingenuity Knowledge Base (Genes+Endogenous Chemicals) was used as a reference set.

Results
=======

LC-MS/MS identified 588 named and 53 unnamed metabolites among the 25 leiomyoma and 17 myometrium samples ([Figure 1](#fig1){ref-type="fig"}). Genetic-driver changes had stronger effect on global metabolomic profiles than menopause status or hormone treatment of the patients ([Supplementary Figure S2A](#sup1){ref-type="supplementary-material"}). Leiomyomas of the *FH* subtype displayed a clearly distinct metabolomic profile according to the PCA ([Figure 1](#fig1){ref-type="fig"}) and the hierarchical clustering analysis ([Supplementary Figure S2A](#sup1){ref-type="supplementary-material"}). Leiomyomas of the *FH*, *MED12*, and *HMGA2* subtypes were distinguishable from each other and from the myometrium based on abundancies of metabolites belonging to multiple different categories ([Figure 2](#fig2){ref-type="fig"}). The metabolites that most significantly correlated with tumour size were tryptophan betaine (*r*=0.65, 95% confidence interval 0.35 to 0.83, *q*-value=0.082) and glucose (*r*=−0.64, 95% confidence interval −0.83 to −0.33, *q*-value=0.089, [Supplementary Table S2](#sup1){ref-type="supplementary-material"}).

To identify dysregulated metabolites in the complete set of leiomyomas, we compared all 25 leiomyomas against the corresponding 17 myometrial tissue specimens. Although patient-of-origin was a major source of variation across all metabolites ([Supplementary Figure S2B](#sup1){ref-type="supplementary-material"}), 70 metabolites were significantly dysregulated between leiomyoma and myometrium samples across all patients (*q*-value \<0.1, [Supplementary Table S3](#sup1){ref-type="supplementary-material"}). The most significant metabolite was homocarnosine (FC −14.7), downregulated in all leiomyomas regardless of subtype ([Figure 3](#fig3){ref-type="fig"}). To identify dysregulated metabolites in leiomyomas of the *FH*, *MED12*, *HMGA2*, and triple wild-type subtypes, we compared leiomyomas of each subtype against all myometrial tissue specimens. This revealed 170, 104, 35, and 22 significant metabolites, respectively (*q*-value \<0.1, [Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Most of the significantly dysregulated metabolites were increased in leiomyomas of the *FH* (118/170; 69%) and *HMGA2* (21/35; 60%) subtypes, whereas in the *MED12* (15/104; 14%) and triple wild-type subtypes (4/22, 18%) only a small proportion of the significantly aberrant metabolite levels showed increase ([Figures 1C and D](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Owing to the limited number of *HMGA2*-overexpressing leiomyomas, we describe only changes supported by both metabolic and expression data in this subtype or detectable in multiple subtypes.

Many cofactors and vitamins were altered in all leiomyomas or in specific subtypes. Haeme and biliverdin, which link to haemoglobin and porphyrin metabolism, were reduced in all leiomyoma subtypes ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}, [Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Ascorbate (vitamin C) and aldarate metabolism was altered in leiomyomas of the *MED12* and triple wild-type subtypes ([Table 1](#tbl1){ref-type="table"}); the level of ascorbate itself remained unaltered, but the levels of dehydroascorbate, threonate, and gulonate were reduced. IPA predicted dysregulation of the antioxidant action of vitamin C pathway in leiomyomas of the *MED12* subtype based on both metabolic and gene expression data ([Table 2](#tbl2){ref-type="table"}). Similarly, retinol (vitamin A) was significantly reduced in the *MED12* and triple wild-type subtypes (FC −2.5 and −1.8, respectively). Based on previous studies, vitamin D deficiency contributes to the development of leiomyomas ([@bib6]); no vitamin D metabolites were detected in our study samples.

The alterations affecting amino-acid metabolites varied between leiomyoma subtypes. *FH*-deficient leiomyomas displayed significant accumulation of urea cycle metabolites argininosuccinate (FC 38.5, [Figure 3](#fig3){ref-type="fig"}), proline (FC 1.5, [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}), citrulline (FC 1.4), dimethylarginine (FC 2.5), trans-4-hydroxyproline (FC 1.7), and N-monomethylarginine (FC 1.6). The levels of leucine, isoleucine, and valine metabolites 3-methyl-2-oxobutyrate (FC 8.3), 4-methyl-2-oxopentanoate (FC 6.5), and 3-methyl-2-oxovalerate (FC 4.7) were notably elevated in leiomyomas of the *FH* subtype. Leiomyomas of the *HMGA2* subtype displayed accretion of the polyamine metabolites N-acetylputrescine (FC 11.3) and N(4)-acetylspermidine (FC 7.7), the latter of which was also elevated in the *FH* subtype (FC 5.2). Furthermore, IPA predicted dysregulation of putrescine degradation III in the *HMGA2* subtype based on both metabolomic and gene expression data ([Table 2](#tbl2){ref-type="table"}). In leiomyomas of the *MED12* subtype, the pathway enrichment analysis of the metabolomic data revealed significant dysregulation of methionine, cysteine, S-adenosylmethionine (SAM), and taurine metabolism as well as significant reduction of dipeptides ([Table 1](#tbl1){ref-type="table"}). In addition, multiple amino acids and their derivatives were specifically decreased in the *MED12* subtype, including histamine (FC −35.9, [Figure 3](#fig3){ref-type="fig"}), phenylalanine (FC −2.2, [Figure 3](#fig3){ref-type="fig"}), leucine (FC −1.5, [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}), isoleucine (FC −1.5), lysine (FC −1.5), arginine (FC −1.4), argininosuccinate (FC −1.9, [Figure 3](#fig3){ref-type="fig"}), tyrosine (FC −2.0), and tryptophan (FC −1.5).

Leiomyomas displayed alterations in a wide array of lipid classes. The pathway enrichment analysis revealed significant dysregulation of sphingolipid metabolism in all subtypes except triple wild-type leiomyomas ([Table 1](#tbl1){ref-type="table"}). Especially leiomyomas of the *MED12* subtype showed considerable enrichment of sphingolipid alterations characterised by significant reduction of 23 out of 38 (60.5%) detected sphingolipids. In addition, IPA predicted dysregulation of sphingosine 1-phosphate signalling in the *HMGA2* subtype at both the metabolic and transcriptional levels ([Table 2](#tbl2){ref-type="table"}). Phosphatidylserines were reduced especially in leiomyomas of the *MED12* subtype ([Table 1](#tbl1){ref-type="table"}). Plasmalogens, diacylglycerols, and monohydroxy fatty acids were primarily elevated in both the *FH* and *HMGA2* subtypes ([Table 1](#tbl1){ref-type="table"}, [Supplementary Table S3](#sup1){ref-type="supplementary-material"}).

As expected, several components of the TCA cycle were significantly elevated in leiomyomas of the *FH* subtype, including fumarate (FC 12.0, [Figure 3](#fig3){ref-type="fig"}), malate (FC 10.5, [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}), alpha-ketoglutarate (*α*KG, FC 5.1), succinate (FC 4.1), and 2-methylcitrate/homocitrate (FC 2.0). The pathway enrichment analysis confirmed significant dysregulation of TCA cycle metabolism ([Table 1](#tbl1){ref-type="table"}). Both metabolomic and gene expression data suggested an increased flux through the pentose phosphate pathway (PPP): activation was supported by upregulation of PPP enzymes, such as glucose-6-phosphate dehydrogenase (FC 3.7), phosphogluconate dehydrogenase (FC 3.0), and transketolase (FC 4.3), and depletion of key metabolites ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}).

To identify the most uniquely dysregulated metabolites as potential biomarkers for leiomyomas of the *FH* and *MED12* subtypes, we compared leiomyomas of these subtypes against all the other tumour and normal samples ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}). We detected 240 and 75 subtype-specific metabolites (*q*-value \<0.1) in leiomyomas of the *FH* and *MED12* subtypes, respectively. [Figure 3](#fig3){ref-type="fig"} illustrates the levels of the most uniquely dysregulated metabolites for both subtypes. To identify dysregulated main categories of metabolites, we performed metabolite set ANOVA. The *FH* subtype displayed a significant overall increase of energy, lipid, and nucleotide metabolites, whereas the *MED12* subtype displayed a significant overall decrease of cofactors and vitamins, peptides, and unnamed metabolites, and the triple wild-type leiomyomas displayed significant reduction of cofactors and vitamins ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}).

Discussion
==========

This study explored the global metabolomic profiles of 25 uterine leiomyomas representing the three main molecular subtypes: leiomyomas driven by *FH* deficiency, a *MED12* mutation, or *HMGA2* upregulation. Altogether 70 metabolites were commonly dysregulated in all leiomyomas. We found that *FH-*deficient leiomyomas represent, as expected, a metabolically distinct subtype of leiomyomas and that these leiomyomas can be distinguished based on their metabolomic profile, whereas the metabolic changes in the other subtypes were subtler. Leiomyomas of the *FH* subtype displayed predominantly accumulation of metabolites, whereas the changes in the *MED12* subtype were mainly decreases. It is intriguing to speculate that the overall reduction of metabolites may limit the supply of building blocks and thereby explain the significantly smaller size of leiomyomas of the *MED12* subtype ([@bib23]).

Leiomyomas of all subtypes displayed reduction of specific vitamin and other cofactor metabolites, suggesting alterations in redox state, enzyme function, and signalling pathways. We detected a significant reduction of retinoic acid (RA) precursor retinol (vitamin A) in leiomyomas of the *MED12* and triple wild-type subtypes. Furthermore, gene expression data revealed RA receptor activation as one of the most significantly dysregulated pathways in leiomyomas ([@bib34]). Reduced retinol levels may reflect a decreased concentration of biologically active RA and increased rate of RA metabolism, which has been previously observed in leiomyomas ([@bib11]). Furthermore, all-*trans*-RA, synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR), and RA metabolism-blocking agent liarozole have been shown to reduce leiomyoma cell proliferation and extracellular matrix production ([@bib8]; [@bib30]; [@bib19]). Essentially, 4-HPR and liarozole have been well tolerated in clinical studies ([@bib14]; [@bib9]). The metabolites of ascorbate (vitamin C) were also depleted, and based on the gene expression data, the antioxidant action of vitamin C was predicted to be activated in leiomyomas of the *MED12* subtype. In addition to antioxidant response, these alterations in vitamin C metabolites may reflect adaptations in other important cellular processes including DNA and histone demethylation, and the nuclear factor-*κ*B-mediated signalling ([@bib13]; [@bib55]). In particular, the depletion of vitamin C metabolites may link to the abundance of extracellular matrix in leiomyomas, as vitamin C is a cofactor in collagen synthesis ([@bib15]). Epidemiological studies have found no association between vitamin C and leiomyoma risk, whereas results regarding retinol levels and leiomyoma risk are contradictory ([@bib32]; [@bib53]), thus further research on their use as preventive agents is warranted.

As a novel finding, the levels of haeme, a fundamental co-factor in cellular respiration and signal transduction, and its degradation product biliverdin were reduced in all leiomyomas, suggesting that haeme metabolism has an important role in leiomyomagenesis. As the cataplerotic haeme biosynthesis uses TCA-cycle-derived carbon and haeme degradation produces bilirubin to be excreted, increased haeme metabolism promotes removal of accumulated TCA cycle metabolites especially in *FH*-deficient leiomyomas, in which the expression of haeme-degrading-enzyme gene, *haeme oxygenase 1* (*HMOX1*) is upregulated ([@bib17]; [@bib34]). Moreover, the inhibition of haeme biosynthesis and degradation pathway has demonstrated to be synthetic lethal with *FH* deficiency ([@bib17]). Although the mechanisms underlying these alterations in haeme metabolism are likely to be different in leiomyomas of the *FH* subtype than in the other leiomyomas, targeting haeme metabolism may serve as valuable strategy to treat all leiomyomas, regardless of subtype.

The leiomyoma subtypes harboured multiple different alterations affecting peptide and amino-acid metabolites, which are necessary building blocks and energy sources for tumours. Homocarnosine, which is a dipeptide derivative predominantly found in the central nervous system, was abundant across all myometrium samples and detected at markedly reduced levels in all leiomyomas. The biological function of homocarnosine remains largely unclear, although as an antioxidant it may be important in counteracting oxidative stress ([@bib26]). No previous data seem to exist on the levels of homocarnosine in normal myometrium and further studies are required to understand the role of homocarnosine in this tissue type. Specifically, leiomyomas of the *MED12* subtype displayed reduction of various amino acids, their derivatives, and dipeptides, possibly reflecting increased protein synthesis. These leiomyomas showed also enrichment of dysregulated methionine, cysteine, SAM, and taurine metabolites. The observed reduction of taurine is compatible with a previous report ([@bib33]). As SAM is the major coenzyme in reactions with methyl group transfer, these changes may reflect altered methylation of proteins and DNA in leiomyomas of the *MED12* subtype ([@bib48]; [@bib43]). On the contrary, *FH*-deficient leiomyomas displayed accretion of valine, leucine, and isoleucine metabolites, suggesting that blockage of the TCA cycle impairs the function of the branched-chain alpha-keto acid dehydrogenase complex, which belongs to the mitochondrial dehydrogenase complex family and is essential in the metabolism of these amino acids ([@bib22]). In addition, leiomyomas of the *FH* and *HMGA2* subtypes displayed accretion of polyamines, which has been implicated in induction of cell proliferation and reduction of apoptosis ([@bib18]). Targeting polyamine metabolism may prove an effective therapy or, more importantly, a prevention mechanism for these leiomyoma subtypes, as indicated by a prior study showing that treatment with 2-difluoromethylornithine, a well-tolerated inhibitor of a central enzyme in polyamine synthesis, limits the growth of leiomyoma cells ([@bib8]; [@bib18]).

All leiomyomas displayed alterations in a wide array of lipid classes, yet with subtype specific differences. Levels of sphingolipids and phosphatidylserines, which are structural components of cell membranes, were especially reduced in leiomyomas of the *MED12* subtype. Sphingolipids are signal transducers that regulate apoptosis and proliferation ([@bib41]). Phosphatidylserines also have a role in signalling pathways and they mediate humoral and cellular processes, including blood coagulation and phagocytosis ([@bib52]). In contrast, other important components of cell membranes, plasmalogens and diacylglycerols, were increased in leiomyomas of the *FH* and *HMGA2* subtypes. These lipids affect the membrane properties and facilitate various signalling processes ([@bib21]; [@bib7]). All these deregulations in lipid metabolites presumably contribute to leiomyoma development on many levels, not only by providing an energy source and building blocks for membrane biogenesis during cell growth but also by regulating signalling pathways involved in proliferation and differentiation.

The most apparent effect of *FH* deficiency was intracellular fumarate accumulation, which is considered tumour promoting ([@bib1]). Additionally, *FH*-deficient leiomyomas displayed accumulation of other TCA cycle intermediates malate, succinate, *α*KG, and homocitrate. Prior studies using HLRCC-related tumours, *FH*-deficient kidney cells and tissues from mice, and a metastatic kidney cancer cell line from an HLRCC patient have detected accumulation of fumarate and succinate but have provided contradicting data on the levels of malate, *α*KG, and citrate ([@bib44]; [@bib17]; [@bib50]; [@bib2]; [@bib54]; [@bib56]). Furthermore, patients with congenital fumarase deficiency, a rare autosomal-recessive disorder, display increased levels of fumarate, succinate, *α*KG, citrate, and malate in their physiological fluids ([@bib3]; [@bib51]). [@bib38] demonstrated that human-derived *FH*-deficient kidney cancer cells use glutamine-dependent reductive carboxylation of *α*KG to produce citrate, acetyl coenzyme A, and remaining four-carbon TCA intermediates. This reductive carboxylation supports fatty acid synthesis allowing *FH-*deficient cells to maintain growth ([@bib38]). Studies using *FH*-deficient mouse cell lines, however, observed no evidence of reductive carboxylation ([@bib17]; [@bib2]). As increased *α*KG/citrate ratio triggers reductive glutamine metabolism ([@bib16]), our results suggest that reductive carboxylation occurs in *FH*-deficient leiomyomas, but isotope-labelling studies using leiomyoma cell lines would be required for confirmation.

Based on the current knowledge of the tumourigenic mechanism of *FH*-deficiency, accumulation of intracellular fumarate activates transcription factor nuclear factor (erythroid-derived 2)-like 2 (NRF2) ([@bib1]). NRF2 is a master regulator of antioxidant responses and it redirects glucose and glutamine into anabolic pathways including the PPP, which is an efficient source of NADPH ([@bib37]; [@bib20]). The gene expression data revealed a highly significant activation of NRF2-mediated oxidative stress response in leiomyomas of the *FH* subtype causing, for example, upregulation of *HMOX1* ([@bib20]; [@bib34]). This is further supported by our metabolomic and gene expression data as *FH-*deficient leiomyomas displayed several metabolic alterations known to be affected by activated NRF2 including increased PPP flux, validating an observation made previously in *FH*-deficient kidney cancer cell lines ([@bib54]). All in all, NRF2 activation supports *FH-*deficient cell proliferation by enhancing PPP and generating NADPH, which is critical for reductive carboxylation of glutamine-derived *α*KG, synthesis of fatty acids, and protection against oxidative stress.

Our analysis discovered putative biomarkers for *FH* deficiency including argininosuccinate and N6-succinyladenosine (S-ado). Argininosuccinate is a precursor to fumarate via argininosuccinate lyase (ASL) and S-ado is formed by dephosporylation of adenylosuccinate, a substrate of adenylosuccinate lyase (ADSL) that normally catalyzes formation of fumarate. *FH-*deficient cells seem to control the levels of fumarate by reversing or inhibiting the reactions catalyzed by ASL and ADSL leading to argininosuccinate and S-ado accumulation ([@bib2]; [@bib56]; [@bib25]). *FH*-deficient kidney specimens from mice as well as physiological fluids of patients with congenital fumarase deficiency display increased levels of adenylosuccinate, providing further support for the inhibition of ADSL activity in *FH-*deficient tissues ([@bib3]; [@bib2]; [@bib51]). The usefulness of S-ado as a biomarker and its tumourigenic role require further research. Argininosuccinate is normally produced in the urea cycle. *FH*-deficient kidney cancers employ exogenous arginine to produce argininosuccinate and blocking this mechanism reduces proliferation of these cells, suggesting that the arginine pathway is essential for the growth of *FH-*deficient tumours ([@bib2]; [@bib56]). Intriguingly, clinical studies have revealed a tolerable profile for an arginine-depleting drug ([@bib42]). Furthermore, [@bib56] observed abundant secretion of argininosuccinate into the urine of *Fh1*-deficient mice and into the growth media of *FH*-deficient cell lines. Thus, argininosuccinate and arginine metabolism may prove to be a robust metabolic biomarker and a treatment target for HLRCC-associated tumours, respectively.

Taken together, this study discovered novel metabolic alterations in leiomyomas involving vitamin C, various membrane lipid, peptide, and amino-acid metabolites ([Figure 4](#fig4){ref-type="fig"}), which may be essential for the growth of specific leiomyoma subtypes. Our findings show the importance of haeme and polyamine metabolism and validate the dysregulation of vitamin A in primary leiomyoma tissues. The results revealed the consequences of impaired TCA cycle associated with *FH*-deficient leiomyomas pinpointing biomarkers and potential therapeutic targets. Importantly, well-tolerated drugs tested in patient trials exist for many of these aberrant states.

To our knowledge, this is the first study that employs a global metabolomics approach to analyse uterine leiomyomas and corresponding myometrium. We have previously shown that the main genetic drivers of uterine leiomyomas result in distinct gene expression profiles ([@bib34]). Here we show that these genetic drivers lead to differences in the metabolomic profiles as well. Our results highlight the diversity of metabolic alterations that can underlie a similar clinical phenotype. The dysregulated metabolites identified in this study may prove to be useful biomarkers and targets for prevention and treatment of uterine leiomyomas, although future studies with larger sample sets are warranted, especially for leiomyomas with *HMGA2* overexpression. Furthermore, metabolic flux studies are required to determine whether the observed changes are derived from altered flux through a pathway or altered synthesis, degradation, or transport of the metabolites. The metabolomic profile of uterine leiomyomas will contribute to understanding pathophysiology of uterine leiomyomas and provides a promising foundation for therapeutic development.
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![**Overview of the metabolomic data.** (**A**) A total of 641 metabolites were identified in the study. (**B**) Principal component analysis revealed five outlier samples (circle) and grouping of leiomyomas of the *FH* subtype together, while the rest of the samples were intermixed. Venn diagrams illustrating the number of significantly (**C**) increased and (**D**) decreased metabolites (*q*-value \<0.1) among leiomyomas of the *FH*, *MED12*, *HMGA2*, and triple wild-type subtypes.](bjc2017361f1){#fig1}

![**Supervised hierarchical clustering analysis with 63 metabolites comprising the 20 most significant metabolites of each leiomyoma subtype.**](bjc2017361f2){#fig2}

![**Levels of the most significantly dysregulated metabolites.** Homocarnosine was the most significantly dysregulated metabolite in all leiomyomas. Fumarate, N6-succinyladenosine (S-ado), and argininosuccinate were the most uniquely dysregulated metabolites in leiomyomas of the *FH* subtype. Histamine and phenylalanine were the most uniquely dysregulated metabolites in leiomyomas of the *MED12* subtype.](bjc2017361f3){#fig3}

![**Schematic of the highlighted metabolic alterations in leiomyomas of the *FH* and *MED12* subtypes.** All leiomyomas displayed reduced homocarnosine and haeme metabolite levels and subtype-specific alterations in lipids. (**A**) *FH-*deficient leiomyomas displayed dysregulation of TCA cycle, PPP, and the metabolism of amino acids and nucleotides. (**B**) *MED12-*mutated leiomyomas harboured alterations affecting retinol, ascorbate, amino acids, and dipeptides. ADSL=adenylosuccinate lyase; ASL=argininosuccinate lyase; BCAA=branched chain amino acid; BCKDC=branched-chain alpha-keto acid dehydrogenase complex; FH=fumarate hydratase; HMOX1=haeme oxygenase 1; MED12=mediator complex subunit 12; NRF2=nuclear factor (erythroid-derived 2)-like 2; PPP=pentose phosphate pathway; S-ado=N6-succinyladenosine; SAM=S-adenosylmethionine; TCA=tricaboxylic acid.](bjc2017361f4){#fig4}

###### Significantly dysregulated pathways predicted from metabolomic data by pathway enrichment analysis for each leiomyoma subtype

  **Pathway**                                         **Enrichment score**   **Enrichment** ***P-*****value**   **Proportion of significant metabolites in pathway (%)**    **Metabolites significantly increased/decreased**
  --------------------------------------------------- ---------------------- ---------------------------------- ---------------------------------------------------------- ---------------------------------------------------
  ***FH***                                                                                                                                                                 
  Plasmalogen                                         5.4                    0.0047                             7/10 (70.0%)                                                                       6/1
  Glycogen metabolism                                 5.3                    0.0048                             4/4 (100.0%)                                                                       4/0
  TCA cycle                                           5.1                    0.0059                             5/6 (83.3%)                                                                        5/0
  Sphingolipid metabolism                             4.6                    0.0096                             17/38 (44.7%)                                                                     7/10
  Pentose phosphate pathway                           4.0                    0.018                              3/3 (100.0%)                                                                       0/3
  Diacylglycerol                                      3.3                    0.036                              8/16 (50.0%)                                                                       8/0
  ***MED12***                                                                                                                                                              
  Sphingolipid metabolism                             22.6                   1.5x10^−10^                        23/38 (60.5%)                                                                     0/23
  Phosphatidylserine                                  5.5                    0.0042                             3/3 (100.0%)                                                                       0/3
  Ascorbate (vitamin C) and aldarate metabolism       4.2                    0.015                              3/4 (75.0%)                                                                        0/3
  Dipeptide                                           3.2                    0.043                              4/9 (44.4%)                                                                        0/4
  Methionine, cysteine, SAM, and taurine metabolism   3.1                    0.044                              5/13 (38.5%)                                                                       1/4
  ***HMGA2***                                                                                                                                                              
  Plasmalogen                                         9.5                    7.5 × 10^−5^                       5/10 (50.0%)                                                                       4/1
  Sphingolipid metabolism                             7.6                    0.00053                            8/38 (21.1%)                                                                       1/7
  Diacylglycerol                                      4.8                    0.0085                             4/16 (25.0%)                                                                       4/0
  Fatty acid, monohydroxy                             3.6                    0.026                              2/5 (40.0%)                                                                        2/0
  **Triple wild type**                                                                                                                                                     
  Haemoglobin and porphyrin metabolism                5.0                    0.0065                             2/4 (50.0%)                                                                        0/2
  Ascorbate (vitamin C) and aldarate metabolism       5.0                    0.0065                             2/4 (50.0%)                                                                        0/2
  Dipeptide derivative                                3.4                    0.034                              1/1 (100.0%)                                                                       0/1
  Vitamin A metabolism                                3.4                    0.034                              1/1 (100.0%)                                                                       0/1

Abbreviations: SAM=S-adenosylmethionine; TCA=tricarboxylic acid.

###### Significantly dysregulated pathways at both the metabolome and transcriptome levels for leiomyomas of the FH, MED12, and HMGA2 subtypes (*P*-value \<0.05 in both metabolomic and gene expression data)

                                                   **Gene expression data**    **Metabolomic data**                                                                                                                                                  
  ------------------------------------------------ -------------------------- ---------------------- ------------------------------------------------------------------------------------------------------------------------------------- --------- ------------------------------------------------------------------------------------
  ***FH***                                                                                                                                                                                                                                           
  Pentose phosphate pathway                        0.041                               NaN                                                                *PGD ↑*, *TKT ↑*, *G6PD ↑*                                                       0.00004    Gluconic acid-6-phosphate ↓, sedoheptulose 7-phosphate ↓, D-ribulose 5-phosphate ↓
  Pentose phosphate pathway (oxidative branch)     0.047                               NaN                                                                     *PGD ↑*, *G6PD ↑*                                                           0.00041                  Gluconic acid-6-phosphate ↓, D-ribulose 5-phosphate ↓
  tRNA splicing                                    0.0011                              NaN                                       *PDE10A ↓*, *PDE3A ↓*, *PDE1B ↑*, *PDE5A ↓*, *PDE8B ↑*, *PDE1A ↑*, *PDE1C ↑*                              0.0087                                   Niacinamide ↑, NAD+ ↓
  Gluconeogenesis I                                0.025                               NaN                                                      *PGK1 ↑*, *ENO1 ↑*, *ENO2 ↑*, *ME1 ↑*, *BPGM ↑*                                            0.0091                                   L-malic acid ↑, NAD+ ↓
  IL-10 signalling                                 0.042                               NaN                                               *IL33 ↑*, *HMOX1 ↑*, *SOCS3 ↓*, *FOS ↓*, *JUN ↓*, *MAP4K4 ↑*                                      0.020                                    Haeme ↓, biliverdine ↓
  Salvage pathways of pyrimidine ribonucleotides   0.045                               NaN                                    *DAPK1 ↓*, *AK1 ↑*, *SGK1 ↓*, *PRKAA2 ↓*, *CDK6 ↑*, *AK4 ↑*, *MAP3K8 ↓*, *LIMK1 ↑*                           0.046                                     Uridine ↑, uracil ↑
  ***MED12***                                                                                                                                                                                                                                        
  Antioxidant action of vitamin C                  0.0022                              2.83                  *PLA2G4A ↓*, *PLCB4 ↓*, *PLCE1 ↓*, *NFKBIA ↓*, *PLCG2 ↓*, *PLA2R1 ↓*, *MAPK10 ↓*, *RARRES3 ↓*, *SLC2A3 ↓*, *TXNRD1 ↓*         0.019                      L-dehydroascorbic acid ↓, glutathione disulphide ↓
  Type II diabetes mellitus signalling             0.0025                             −1.00           *PPARG ↓*, *SOCS3 ↓*, *NFKBIA ↓*, *IRS1 ↑*, *CD36 ↓*, *ACSL5 ↓*, *PRKAA2 ↓*, *MAPK10 ↓*, *IRS4 ↑*, *ACSL4 ↓*, *MAP3K5 ↓*, *PRKD1 ↑*  0.034                                 Sphingomyelin ↓, ceramide ↑
  ***HMGA2***                                                                                                                                                                                                                                        
  Putrescine degradation III                       0.028                               NaN                                                       *ALDH1B1 ↓*, *MAOB ↓*, *ALDH1A1 ↓*, *MAOA ↓*                                              0.011                                     N-acetylputrescine ↑
  Sphingosine-1-phosphate signalling               0.0035                             −1.51                *S1PR3 ↑*, *PLCB4 ↓*, *PLCE1 ↓*, *RND3 ↓*, *PLCG2 ↓*, *PDGFRA ↓*, *GNAI1 ↓*, *PIK3C2G ↑*, *AKT3 ↓*, *PDGFD ↓*, *PDGFC ↑*        0.039                                       Sphingomyelin ↓

Abbreviations: IL=interleukin; NaN=a *z*-score cannot be calculated for all Ingenuity canonical pathways. Note: a positive *z*-score indicates predicted activation, and a negative *z*-score indicates predicted inactivation of the enriched pathway.
